Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997

Gaetano Bacci, S. Ferrari, A. Longhi, D. Donati, M. De Paolis, C. Forni, M. Versari, E. Setola, A. Briccoli, E. Barbieri

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Many papers have reported the results achieved with combined therapy for Ewing's tumors, but little is known about the treatment and outcome of those 30-40% of patients who relapse. Patients and methods: In a retrospective study, we evaluated 195 patients with Ewing's tumors treated at our institution from 1979 to 1997 with chemotherapy, radiotherapy, surgery or combined therapies after recurrence. Results: A second complete remission was achieved in only 26 patients (13.3%); 12 relapsed again and died of the tumor. The 5-year post-relapse event-free survival and overall survival were 9.7% and 13.8%, respectively; both of which were significantly better for patients who had relapsed ≥2 years after the beginning of the first treatment (14.3% versus 2.5%; P

Original languageEnglish
Pages (from-to)1654-1659
Number of pages6
JournalAnnals of Oncology
Volume14
Issue number11
DOIs
Publication statusPublished - Nov 2003

Keywords

  • Ewing's sarcoma
  • Outcome
  • Relapse
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997'. Together they form a unique fingerprint.

Cite this